# Tilray Brands, Inc.: overview

TLRY · Nasdaq · CIK 1731348 · [Healthcare](/sectors/healthcare.md) · fiscal year ends May 31

Pages: [Overview](/companies/tlry.md) · [Financials](/companies/tlry/financials.md) · [Filings](/companies/tlry/filings.md) · [Insiders](/companies/tlry/insiders.md)

Latest reported revenue: [$257.1m](/filings/0001437749-26-032382.md) for Q1 FY2027, three months to 2026-08-31, from the 10-Q filed Oct 8, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-032382).

## Last eight quarters

| Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [211](/filings/0001437749-26-000902.md) | [186](/filings/0001437749-26-010907.md) | [225 d](/filings/0001437749-26-024698.md) | [210](/filings/0001437749-26-032382.md) | [218](/filings/0001437749-26-000902.md) | [207](/filings/0001437749-26-010907.md) | [282 d](/filings/0001437749-26-024698.md) | [257](/filings/0001437749-26-032382.md) |
| Gross margin | % | [29.0%](/filings/0001437749-26-000902.md) | [28.0%](/filings/0001437749-26-010907.md) | [30.1% d](/filings/0001437749-26-024698.md) | [27.4%](/filings/0001437749-26-032382.md) | [26.4%](/filings/0001437749-26-000902.md) | [26.6%](/filings/0001437749-26-010907.md) | [32.1% d](/filings/0001437749-26-024698.md) | [30.1%](/filings/0001437749-26-032382.md) |
| Operating margin | % | [(20.0%)](/filings/0001437749-26-000902.md) | [(409.0%)](/filings/0001437749-26-010907.md) | [(643.1%) d](/filings/0001437749-26-024698.md) | [1.0%](/filings/0001437749-26-032382.md) | [(10.2%)](/filings/0001437749-26-000902.md) | [(12.8%)](/filings/0001437749-26-010907.md) | [(5.8%) d](/filings/0001437749-26-024698.md) | [(9.4%)](/filings/0001437749-26-032382.md) |
| Net margin | % | [(40.5%)](/filings/0001437749-26-000902.md) | [(424.9%)](/filings/0001437749-26-010907.md) | [(566.9%) d](/filings/0001437749-26-024698.md) | [(0.2%)](/filings/0001437749-26-032382.md) | [(20.7%)](/filings/0001437749-26-000902.md) | [(12.9%)](/filings/0001437749-26-010907.md) | [(17.6%) d](/filings/0001437749-26-024698.md) | [(16.8%)](/filings/0001437749-26-032382.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0001437749-26-000902.md) | [(8.69)](/filings/0001437749-26-010907.md) | not reported | [0.00](/filings/0001437749-26-032382.md) | [(0.41)](/filings/0001437749-26-000902.md) | [(0.24)](/filings/0001437749-26-010907.md) | not reported | [(0.32)](/filings/0001437749-26-032382.md) |
| Free cash flow | $m | [(46.2) d](/filings/0001437749-26-000902.md) | [(20.2) d](/filings/0001437749-26-010907.md) | [(19.1) d](/filings/0001437749-26-024698.md) | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [628](/filings/0001437749-24-023774.md) | [627](/filings/0001437749-25-023703.md) | [789](/filings/0001437749-26-024698.md) | [821](/filings/0001437749-26-024698.md) | [915](/filings/0001437749-26-024698.md) |
| Gross margin | % | [18.6%](/filings/0001437749-24-023774.md) | [23.4%](/filings/0001437749-25-023703.md) | [28.3%](/filings/0001437749-26-024698.md) | [29.3%](/filings/0001437749-26-024698.md) | [28.4%](/filings/0001437749-26-024698.md) |
| Operating margin | % | [(97.1%)](/filings/0001437749-24-023774.md) | [(218.4%)](/filings/0001437749-25-023703.md) | [(22.1%)](/filings/0001437749-26-024698.md) | [(277.9%)](/filings/0001437749-26-024698.md) | [(6.9%)](/filings/0001437749-26-024698.md) |
| Net margin | % | [(75.9%)](/filings/0001437749-24-023774.md) | [(231.6%)](/filings/0001437749-25-023703.md) | [(31.1%)](/filings/0001437749-26-024698.md) | [(266.3%)](/filings/0001437749-26-024698.md) | [(13.3%)](/filings/0001437749-26-024698.md) |
| Diluted EPS | $ per share | [(0.99)](/filings/0001437749-24-023774.md) | [(2.35)](/filings/0001437749-25-023703.md) | [(3.30)](/filings/0001437749-26-024698.md) | [(24.56)](/filings/0001437749-26-024698.md) | [(1.09)](/filings/0001437749-26-024698.md) |
| Free cash flow | $m | [(211)](/filings/0001437749-24-023774.md) | [(12.9)](/filings/0001437749-25-023703.md) | [(60.2)](/filings/0001437749-26-024698.md) | [(128)](/filings/0001437749-26-024698.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/tlry/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $18.0m | 4,007,600 | Call | Reduced −904,900 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $14.7m | 3,279,300 | Put | Reduced −505,500 |
| [Tidal Investments LLC](/funds/1600064.md) | 2026-06-30 | $11.2m | 2,498,656 |  | Reduced −65,033 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $4.6m | 1,021,777 |  | Added +479,545 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $4.5m | 995,145 |  | Added +354,120 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $4.0m | 886,500 | Call | Reduced −111,840 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $3.9m | 868,147 |  | Added +854,239 |
| [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $3.6m | 790,910 | Put | Added +181,170 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $2.9m | 648,506 |  | New +648,506 |
| [MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.](/funds/1705339.md) | 2026-06-30 | $2.9m | 646,762 |  | Added +159,942 |

## Recent filings

[All 770 filings](/companies/tlry/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-08 | 21:00 ET | [10-Q](/filings/0001437749-26-032382.md) | Quarterly report, period 2026-08-31 | 0001437749-26-032382 |
| 2026-10-08 | 11:00 ET | [8-K](/filings/0001171843-26-006527.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-006527 |
| 2026-09-28 | 20:00 ET | [DEF 14A](/filings/0001140361-26-037827.md) | Proxy statement, period 2026-11-18 | 0001140361-26-037827 |
| 2026-09-14 | 21:12 ET | [8-K](/filings/0001140361-26-036507.md) | 3.02 Unregistered sale of equity | 0001140361-26-036507 |
| 2026-08-10 | 21:00 ET | [8-K](/filings/0001140361-26-032052.md) | 3.02 Unregistered sale of equity | 0001140361-26-032052 |
| 2026-07-28 | 21:03 ET | [10-K](/filings/0001437749-26-024698.md) | Annual report, period 2026-05-31 | 0001437749-26-024698 |
| 2026-07-28 | 20:05 ET | [8-K](/filings/0001171843-26-004944.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001171843-26-004944 |
| 2026-06-30 | 21:01 ET | [8-K](/filings/0001140361-26-026966.md) | 3.02 Unregistered sale of equity | 0001140361-26-026966 |
| 2026-06-09 | 20:31 ET | [8-K](/filings/0001140361-26-024650.md) | 3.02 Unregistered sale of equity | 0001140361-26-024650 |
| 2026-04-21 | 20:40 ET | [8-K](/filings/0001140361-26-015921.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001140361-26-015921 |

## Latest annual report

[Form 10-K for the fiscal year ended May 31, 2026](/filings/0001437749-26-024698.md), filed Jul 28, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1731348
- Tickers: TLRY
- Exchange: Nasdaq
- SIC code: 2833 Medicinal Chemicals & Botanical Products
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.